Tocilizumab is safe and tolerable and reduces C‐reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients.

Published in:

Muscle & Nerve, 2021, v. 64, n. 3, p. 309, doi. 10.1002/mus.27339

By:

• Milligan, Carol;
• Atassi, Nazem;
• Babu, Suma;
• Barohn, Richard J.;
• Caress, James B.;
• Cudkowicz, Merit E.;
• Evora, Armineuza;
• Hawkins, Gregory A.;
• Wosiski‐Kuhn, Marlena;
• Macklin, Eric A.;
• Shefner, Jeremy M.;
• Simmons, Zachary;
• Bowser, Robert P.;
• Ladha, Shafeeq S.

Publication type:

Article